CRNX - Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Crinetics will receive $85.00 in cash for each share of Crinetics that they own. KSF is seeking to determine whether this consideratio.

Jul 08, 2026 08:33 AM • businesswire.com (Hide legal announcements)

Vertex's Crinetics Deal Balances Growth with Integration Risk

Vertex Pharmaceuticals NASDAQ: VRTX recently announced its plans to acquire Crinetics Pharmaceuticals NASDAQ: CRNX for $10 billion. The deal, which has already been approved by the board of directors of both companies, is expected to close in the third quarter of 2026.

Jul 08, 2026 05:05 AM • marketbeat.com

Strength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength?

CRINETICS PHARM (CRNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Jul 07, 2026 11:55 PM • zacks.com

Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.

Crinetics' Palsonify was FDA-approved late last year. The company's atumelnant is currently in late Phase 3 clinical testing.

Jul 07, 2026 11:28 PM • fool.com

Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.

Vertex agreed to buy Crinetics for $85 per share in cash, about $10 billion in equity value. The deal adds a newly launched acromegaly drug and a late-stage candidate with more than $5 billion in combined peak-sales potential.

Jul 07, 2026 07:00 PM • fool.com

CRNX Stock Alert: Halper Sadeh LLC is Investigating Whether Crinetics Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.  The proposed transaction may contain terms that could limit superior competing offers.

Jul 07, 2026 07:45 AM • globenewswire.com

VRTX to Strengthen Rare Disease Portfolio With $10B Crinetics Buyout

Vertex to acquire CRNX for $10B, adding approved rare disease drug Palsonify and late-stage pipeline assets to expand its endocrinology portfolio.

Jul 07, 2026 06:31 AM • zacks.com

Crinetics shares surge after Vertex agrees to $10B cash buyout

Crinetics Pharmaceuticals shares surged after Vertex Pharmaceuticals announced an agreement to acquire the endocrinology-focused biotech company in a deal valued at approximately $10 billion. The all-cash transaction values Crinetics at $85 per share and is expected to close during the current quarter, subject to customary conditions.

Jul 07, 2026 05:38 AM • invezz.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - July 7, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Crinetics Pharmaceuticals, Inc. ("Crinetics Pharmaceuticals" or the "Company") (NASDAQ: CRNX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The investigation concerns whether the Crinetics Pharmaceuticals Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.

Jul 07, 2026 05:28 AM • newsfilecorp.com

Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday agreed to acquire Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) for $85 per share in cash, a total equity value of approximately $10 billion ($8.8 billion net of cash).

Jul 07, 2026 04:24 AM • benzinga.com

Breakfast News: Vertex Bets $10B to Win $5B a Year

Vertex snaps up Crinetics, Synopsys pivots to higher-margin AI offerings, and more

Jul 07, 2026 03:30 AM • fool.com

Samsung, Micron, Rivian, SpaceX, Crinetics, and More Stocks That Explain Today's Market

AI stocks take a beating, with South Korean memory-chip maker Samsung Electronics setting the tone for the broader market.

Jul 07, 2026 02:35 AM • barrons.com

Why Crinetics Pharmaceuticals Shares Are Trading Higher By 99%; Here Are 20 Stocks Moving Premarket

Shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) rose sharply in pre-market trading after the company announced it will be acquired by Vertex Pharmaceuticals (NASDAQ:VRTX).

Jul 07, 2026 12:49 AM • benzinga.com

Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE, July 6, 2026 /PRNewswire/ -- Ademi LLP is investigating Crinetics (Nasdaq: CRNX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Vertex. Click here  to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

Jul 06, 2026 03:41 PM • prnewswire.com (Hide legal announcements)

CRNX Stock Alert: Halper Sadeh LLC is Investigating Whether Crinetics Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) to Vertex Pharmaceuticals Incorporated for $85.00 per share in cash. Halper Sadeh encourages Crinetics shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Crinetics a.

Jul 06, 2026 01:53 PM • businesswire.com

Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10 Billion

The acquisition would add to Vertex's pipeline and potentially grow its annual revenue by $5 billion with the addition of Crinetics-developed drugs Palsonify and Atumelnant, the company said.

Jul 06, 2026 01:02 PM • wsj.com

Crinetics Pharmaceuticals Stock Doubles After The Close: Here's Why

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) shares are trading higher in Monday's after-hours session after the company announced it will be acquired by Vertex Pharmaceuticals Inc (NASDAQ:VRTX).

Jul 06, 2026 12:30 PM • benzinga.com

Vertex to buy Crinetics in $10 billion deal

Vertex ​Pharmaceuticals ‌will buy ​Crinetics ​Pharmaceuticals ⁠for ​a total ​equity value ​of ​about $10 billion, ‌the ⁠companies said ​on ​Monday.

Jul 06, 2026 12:10 PM • reuters.com

Vertex to Acquire Crinetics Pharmaceuticals

BOSTON & SAN DIEGO--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately.

Jul 06, 2026 12:04 PM • businesswire.com

Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026

SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

Jun 30, 2026 12:05 PM • globenewswire.com

Crinetics downgraded to Hold from Buy at Stifel

$85.00 (was $83.50)

Alex Thompson · Stifel Nicolaus

Jul 08, 2026 09:15 AM • TheFly

Crinetics downgraded to In Line from Outperform at Evercore ISI

$85.00 (was $83.53)

Evercore ISI

Jul 07, 2026 08:58 PM • TheFly

Crinetics downgraded to Hold from Buy at Jefferies

$85.00 (was $42.03)

Jefferies

Jul 07, 2026 10:01 AM • TheFly

Crinetics downgraded to Neutral from Buy at H.C. Wainwright

$85.00 (was $42.03)

H.C. Wainwright

Jul 07, 2026 07:37 AM • TheFly

Crinetics price target raised to $85 from $62 at Baird

$85.00 (was $42.03)

Robert W. Baird

Jul 07, 2026 06:47 AM • TheFly

Crinetics initiated with a Buy at UBS

$55.00 (was $38.68)

Ashwani Verma · UBS

Jul 02, 2026 04:38 AM • TheFly

Stifel Reiterates Buy Rating on Crinetics (CRNX)

$83.00 (was $36.06)

Alex Thompson · Stifel Nicolaus

Jun 22, 2026 09:34 AM • StreetInsider

H.C. Wainwright Reiterates Buy Rating on Crinetics (CRNX)

$81.00 (was $34.47)

Douglas Tsao · H.C. Wainwright

Jun 15, 2026 06:48 AM • StreetInsider

Crinetics price target lowered to $88 from $89 at Evercore ISI

$88.00 (was $37.71)

Gavin Clark-Gartner · Evercore ISI

May 15, 2026 08:22 AM • TheFly

Crinetics price target lowered to $84 from $87 at Oppenheimer

$84.00 (was $37.80)

Oppenheimer

May 11, 2026 07:54 AM • TheFly

Crinetics price target raised to $84 from $75 at Stifel

$84.00 (was $52.44)

Stifel Nicolaus

Jan 30, 2026 07:33 AM • TheFly

Crinetics upgraded to Buy from Neutral at Goldman Sachs

$67.00 (was $53.25)

Richard Law · Goldman Sachs

Jan 12, 2026 05:29 AM • TheFly

Crinetics price target raised to $87 from $80 at Morgan Stanley

$87.00 (was $52.82)

Morgan Stanley

Jan 08, 2026 07:45 AM • TheFly

Crinetics (CRNX) PT Lowered to $105 at Citizens: Palsonify Experience Positive

$105.00 (was $53.34)

China Renaissance Securities (US) Inc.

Jan 08, 2026 04:26 AM • StreetInsider

Crinetics price target raised to $90 from $80 at Evercore ISI

$90.00 (was $51.26)

Evercore ISI

Jan 05, 2026 10:25 AM • TheFly

Stifel Reiterates Buy Rating on Crinetics (CRNX)

$75.00 (was $50.57)

Alex Thompson · Stifel Nicolaus

Jan 05, 2026 10:04 AM • StreetInsider

Crinetics price target raised to $87 from $73 at Oppenheimer

$87.00 (was $43.51)

Oppenheimer

Sep 30, 2025 07:49 AM • TheFly

Crinetics price target raised to $77 from $65 at Morgan Stanley

$77.00 (was $45.91)

Morgan Stanley

Sep 28, 2025 04:42 PM • TheFly

Crinetics price target raised to $143 from $86 at Citizens JMP

$143.00 (was $45.91)

Jonathan Wolleben · JMP Securities

Sep 26, 2025 04:39 AM • TheFly

Crinetics initiated with a Neutral at Goldman Sachs

$36.00 (was $31.99)

Richard Law · Goldman Sachs

Jul 10, 2025 05:13 AM • TheFly